Tivantinib 100 mg | 99.95%
TargetMol
Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
More Information Supplier PageTivantinib
Search Results
LY-411575 100 mg | 97.03%
TargetMol
LY-411575, a potent γ-secretase inhibitor, is with IC50 of 0.078 nM in the membrane and 0.082 nM in cell-based. It also suppresses Notch clevage with IC50 of 0.39 nM.
More Information Supplier PageLY-411575
(-)-Blebbistatin 100 mg | 99.59%
TargetMol
(-)-Blebbistatin is an S enantiomer of blebbistatin. It is a potent and selective myosin II inhibitor with IC50 ranging from 0.5 to 5 μM.
More Information Supplier Page(-)-Blebbistatin
(-)-Blebbistatin 25 mg | 99.59%
TargetMol
(-)-Blebbistatin is an S enantiomer of blebbistatin. It is a potent and selective myosin II inhibitor with IC50 ranging from 0.5 to 5 μM.
More Information Supplier Page(-)-Blebbistatin
XL388 1 mg | 99.39%
TargetMol
XL388 is a highly effective, specifc, ATP-competitive inhibitor of mTOR ( IC50: 9.9 nM), 1000-fold selectivity than the closely related PI3K kinases.
More Information Supplier PageXL388
Danoprevir 25 mg | 99.52%
TargetMol
Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease(IC50=0.2-3.5 nM) of hepatitis C virus (HCV).
More Information Supplier PageDanoprevir
Romidepsin 2 mg | 99.53%
TargetMol
Romidepsin is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed cutaneous and peripheral T cell lymphomas.
More Information Supplier PageRomidepsin
Ki20227 50 mg | 97.16%
TargetMol
Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451/217 nM), respectively.
More Information Supplier PageKi20227
Ki20227 10 mg | 97.16%
TargetMol
Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451/217 nM), respectively.
More Information Supplier PageKi20227
Ki20227 5 mg | 97.16%
TargetMol
Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451/217 nM), respectively.
More Information Supplier PageKi20227